Evaluation of Treatment Patterns and Costs in Patients with Prostate Cancer and Bone Metastases

Abstract

Field Data Generation and Observational Studies team. In this role, Wen is responsible for leading the development and implementation of U.S. Data Generation and Observational Studies research in the field. In addition, she leads the dissemination and communication of health economics and outcomes data for health plans, integrated delivery networks, and other health care systems such as the Department of Veterans Affairs Medical Centers. Wen has a bachelor of science degree in pharmacy, a master of science degree, and a doctorate in pharmacy administration from the University of Texas at Austin. She completed a postdoctoral fellowship in health services research at the Veterans Evidence-Based Research Dissemination and Implementation Center at the South Texas Veterans Health Care System in San Antonio. She currently resides in Jackson, Mississippi.Jianying Yao, MS, is an Associate Director at Bayer Pharmaceuticals with the Global Data Analytics Group in Data Generation and Observational Studies team. Yao is a senior biostatistician, with 20+ years of extensive experience in designing and conducting health outcomes research. She is seasoned in advanced quantitative and analytical skills over large relational databases, with strong expertise in integrated medical and pharmacy claims data analytics. Yao holds a master of science degree in biostatistics from the University of Illinois at Chicago and a bachelor of science degree in physics from the Shanghai Second Institute of Education.

Treatment patterns of prostate cancer with bone metastasis in Beijing: A real‐world study using data from an administrative claims database

“…Similar treatment patterns were observed by Seal et al in a hospital database study . However, for the specific drugs used in each class of treatment, patterns found in our study differed from that in a US population, mainly because newer agents such as abiraterone, denosumab, radium‐233, and sipuleucel‐T were neither approved nor reimbursed in China during the study period and so were not captured in the database.…”

Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone

“…A recent study, using real-world data from patients with chemotherapy-naïve mCRPC in a commercially insured population, reported lower HCRU and PC-related inpatient and emergency department costs for enzalutamide compared with abiraterone [ 18 ]. Another recent real-world study described treatment patterns, healthcare costs, and survival in patients with mCRPC who were commercially insured or Medicare covered and showed that enzalutamide and abiraterone were the most common first-line treatments (more than 65% in total); however, no direct cost comparisons between the treatments were reported [ 19 ].…”

Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study

“…As claims data are routinely collected for billing and reimbursement, information on clinical parameters, such as cancer stage or tumor type, were not available for patient selection or cost stratification. Moreover, as already stated [32], we did not find a completely validated algorithm identifying patients with mCRPC in the literature. However, consulting a clinical expert, we developed an algorithm identifying patients with PC, metastasis, castration resistance, and second-line treatment, using a wide range of different classification systems for claims data.…”